Novel nesprin-1 mutations associated with dilated cardiomyopathy cause nuclear envelope disruption and defects in myogenesis

Can Zhou1,2,†, Chen Li1,2,†, Bin Zhou3,4, Huaqin Sun4,5, Victoria Koullourou1,6, Ian Holt7, Megan J. Puckelwartz8, Derek T. Warren1, Robert Hayward1, Ziyuan Lin4,5, Lin Zhang3,4, Glenn E. Morris7, Elizabeth M. McNally8, Sue Shackleton6, Li Rao2, Catherine M. Shanahan1,‡ and Qiuping Zhang1,*,‡

1King’s College London British Heart Foundation Centre of Research Excellence, Cardiovascular Division, London SE5 9NU, UK, 2Department of Cardiology, West China Hospital of Sichuan University, Chengdu 610041, China, 3Laboratory of Molecular Translational Medicine, 4Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, 5SCU-CUHK Joint Laboratory for Reproductive Medicine, West China Second University Hospital, Sichuan University, Chengdu, 610041, China, 6Department of Molecular and Cell Biology, University of Leicester, Leicester LE1 9HN, UK, 7Wolfson Centre for Inherited Neuromuscular Disease, RJAH Orthopaedic Hospital, Oswestry SY10 7AG, UK and Institute for Science and Technology in Medicine, Keele University, ST5 5BG, UK and 8Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA

†Authors contributed equally to this work.
‡Joint senior authors.

Received: February 10, 2017. Revised: March 22, 2017. Accepted: March 22, 2017

© The Author 2017. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Nesprins-1 and -2 are highly expressed in skeletal and cardiac muscle and together with SUN (Sad1p/UNC84)-domain containing proteins and lamin A/C form the LInker of Nucleoskeleton-and-Cytoskeleton (LINC) bridging complex at the nuclear envelope (NE). Mutations in nesprin-1/2 have previously been found in patients with autosomal dominant Emery–Dreifuss muscular dystrophy (EDMD) as well as dilated cardiomyopathy (DCM). In this study, three novel rare variants (R8272Q, S8381C and N8406K) in the C-terminus of the SYNE1 gene (nesprin-1) were identified in seven DCM patients by mutation screening. Expression of these mutants caused nuclear morphology defects and reduced lamin A/C and SUN2 staining at the NE. GST pull-down indicated that nesprin-1/lamin/SUN interactions were disrupted. Nesprin-1 mutations were also associated with augmented activation of the ERK pathway in vitro and in hearts in vivo. During C2C12 muscle cell differentiation, nesprin-1 levels are increased concomitantly with kinesin light chain (KLC-1/2) and immunoprecipitation and GST pull-down showed that these proteins interacted via a recently identified LEWD domain in the C-terminus of nesprin-1. Expression of nesprin-1 mutants in C2C12 cells caused defects in myoblast differentiation and fusion associated with dysregulation of...
myogenic transcription factors and disruption of the nesprin-1 and KLC-1/2 interaction at the outer nuclear membrane. Expression of nesprin-1Δ9 WT and mutants in zebrafish embryos caused heart developmental defects that varied in severity. These findings support a role for nesprin-1 in myogenesis and muscle disease, and uncover a novel mechanism whereby disruption of the LINC complex may contribute to the pathogenesis of DCM.

Introduction

Dilated cardiomyopathy (DCM) is characterised by dilatation and impaired contraction of the left ventricle or both ventricles, and is an important cause of heart failure and sudden cardiac death, particularly in the young. The genetic causes of DCM are extremely complicated and over 50 genes have been implicated, many of them encoding components of the cytoskeleton and nuclear envelope (NE) (1,2).

Mutations in the LMNA gene, encoding the nuclear intermediate filament proteins lamin A/C, account for 6% of familial DCM patients in addition to causing a wide spectrum of diseases, named laminopathies. The laminopathies include Emery-Dreifuss muscular dystrophy (EDMD), which manifests with skeletal muscle wasting, heart conduction defects (CD) and DCM (3,4). Mutations in the EMD gene, encoding the inner nuclear membrane (INM) protein emerin, a binding partner of lamin A/C, also cause EDMD with CD (5). How mutations in both emerin and lamin A/C, which are ubiquitously expressed proteins, can lead to muscle-specific diseases has been a subject of debate for some time. However, evidence has shown that lamin A/C and emerin are both associated with the Linker of Nucleoskeleton and Cytoskeleton (LINC) bridge complex, which links the nucleus to the actin cytoskeleton. The major components of the LINC complex are: nesprins-1 and -2 (NE-spectrin repeat proteins) and SUN1/SUN2 (6–8). Nesprin-1 and -2 can bind actin via a heterotrimeric interaction at the ONM (80–84), and the N-terminal SUN1/2 isoforms localise at the INM (85–88). These smaller isoforms, in particular, where they bind to emerin, lamin A/C and SUN1/2, forming a sharing spectrin repeats (SRs) in common with the C-terminal nesprin-1 and -2 isoforms, with a truncated N-terminus but -2 isoforms localise at the outer nuclear membrane (ONM) and impaired contraction of the left ventricle or both ventricles, and is an important cause of heart failure and sudden cardiac death, particularly in the young. The genetic causes of DCM are extremely complicated and over 50 genes have been implicated, many of them encoding components of the cytoskeleton and nuclear envelope (NE) (1,2).

Another mechanism that may explain tissue specific disease is muscle-specific expression of LINC complex components. Alternative transcription and splicing of SYNE1 and SYNE2, the genes encoding nesprin-1 and -2, generate multiple isoforms that vary greatly in size (17). The largest giant nesprin-1 and -2 isoforms localise at the outer nuclear membrane (ONM) and connect the nucleus to the actin cytoskeleton. However, smaller nesprin-1 and -2 isoforms, with a truncated N-terminus but sharing spectrin repeats (SRs) in common with the C-terminal regions of the giant proteins, also localise at the INM where they bind to emerin, lamin A/C and SUN1/2, forming a complex at the INM (18). These smaller isoforms, in particular, nesprin-1Δ9 and -2Δ9, are highly and specifically expressed in cardiac and skeletal muscle (7,19). Thus, mutations in SYNE1/2 that disrupt these specific nesprin-1 and -2 isoforms, or mutations in other components of the LINC complex that disrupt their binding with nesprin-1 and -2, are likely to play a key role in muscle-specific laminopathies.

In support of this notion, mutations in the C-terminal regions of the nesprin-1 (SYNE1) and -2 (SYNE2) genes have been identified in patients with muscle specific disorders. This is in contrast to mutations located towards the N-terminus, which are associated with ataxia (13,14,20). For example, several missense mutations in the C-terminus were identified in several small family pedigrees, as well as in sporadic EDMD patients with DCM (13). Studies in fibroblasts from these patients showed abnormal localisation and binding of the LINC complex proteins lamin, emerin and SUN2, as well as nuclear morphology defects and loss of NE integrity. A missense mutation in the same C-terminal region of the SYNE1 gene was identified in a DCM patient, which resulted in increased expression of nesprin-1 and lamin A/C, also indicating a perturbation of the LINC complex (14). Furthermore, nesprin-1 KASH domain knockout (KO) mice developed an EDMD-like phenotype and DCM (21), displaying muscle degeneration with elongated nuclei and reduced heterochromatin. Ablation of the C-terminal regions of both nesprin-1 and -2 in cardiomyocytes resulted in early onset cardiomyopathy (22). These mutant cardiomyocytes exhibited altered nuclear positioning, shape, and chromatin positioning, leading to impairment of gene expression in response to biomechanical stimuli due to loss of either nesprin-1 or -2 or both (22). Finally, in studies in vitro, overexpressing dominant-negative versions of nesprin KASH or SUN proteins in mouse C2C12 myoblasts perturbed the mechanical control of cell differentiation (23). In these studies, nuclear displacement and defects in nuclear rotation were also noted, implicating the LINC complex in myonuclear positioning.

Indeed, recent data have shown that the C-terminal region of nesprin mediates myonuclear positioning by attaching the microtubule (MT) network to the NE during embryonic muscle development and cell migration (24). These interactions occur via the MT motor proteins, dynein and kinesin, the latter being a heterotetramer of two kinesin heavy chain (KHC) subunits - Kif5A, Kif5B, or Kif5C- and two kinesin light chain (KLC)-1/2 subunits. Nesprin-2 was shown to interact with KLC-1/2 at the ONM via a newly identified four-residue tryptophan-acidic (W-acidic) ‘LEWD’ binding motif within an adaptive domain (AD) at its C-terminus, which is present in all muscle-specific isoforms (25–27). Disruption of the LINC complex with a dominant-negative nesprin-2 KASH impaired kinesin-1 association with the NE and induced nuclear aggregation in myotubes (24). As both nesprin-1 and -2 are highly conserved in this C-terminal region, it is likely that nesprin-1 may also mediate the nesprin/ KLC interaction via the ‘LEWD’ binding motif but so far this has not been tested.

In this study, we screened the SYNE1 and SYNE2 genes in 218 DCM patients. We identified three novel nesprin-1 variants (R8272Q, S3813C, and N8406K) in seven patients and investigated their roles in NE organisation and myogenesis.
Results

Identification of three novel nesprin-1 mutants in DCM patients

Mutation screening of both the SYNE1 and SYNE2 genes was performed in 218 sporadic cases of DCM and 210 ethnically matched controls (Supplementary Material, Table S1). 23 exons for nesprin-1 corresponding to nesprin-1α1 and 1α2 and 16 exons for nesprin-2 corresponding to isoforms nesprin-2α2, β2 and β2 were screened. This screening strategy was based on high and specific expression of these isoforms in cardiac and skeletal muscle as well as mapping of the lamin A/C, emerin, SUN and KLC binding sites to domains within these isoforms (19,28–30).

Twelve single nucleotide polymorphisms (SNPs)/variants in SYNE1 were identified, which included intronic sequence variations (n = 2), synonymous (n = 5) and non-synonymous, amino acid exchanges (n = 5). Eight of the variants were not present in 420 control alleles of an ethnically matched reference population (Supplementary Material, Table S2). No nesprin-2 SNPs/variants were identified in the region screened. Interestingly, three of the identified nesprin-1 mutations were unique DNA variants, which resulted in R8272Q, S8381C, N8406K amino acid exchanges in the C-terminus of the nesprin-1 giant as well as within the muscle specific isoform nesprin-1α2, and identified in seven unrelated DCM patients (Fig. 1A, Supplementary Material). The amino acids changed by these missense mutations were in regions that were evolutionarily well conserved and within the mapped emerin and lamin A/C binding domains (25) and also the proposed KLC-1/2 binding domain in nesprin-1 (24,27) (Fig. 1B). The rarity of these variants and their conservation and positioning suggest they may be causative for DCM in the patients examined. ExAC database search revealed that population frequencies for the R8272Q allele were 0.0002145 (26/121204). Further in silico functional analyses showed that all three variants are predicted to cause significant functional impairment for nesprin-1 (Polyphen-2: possibly damaging, SIFT: damaging and Mutation Taster: disease causing). Therefore, all three rare variants were included in further cell biological investigations.

Over-expression of nesprin-1 mutants disrupted nuclear morphology and reduced lamin A/C and SUN2 staining at the NE

We generated GFP-tagged wild-type (WT) and mutant R8272Q, S8381C, N8406K constructs in the context of the muscle specific isoform nesprin-1α2 (Fig. 2A). When transfected into human osteosarcoma (U2OS) cells, abnormalities of nuclear morphology, measured by nuclei circularity, were induced by constructs harbouring the three novel nesprin-1 mutants when compared with WT (Fig. 2B and E). Immunofluorescence (IF) staining showed exogenous expression of the mutants, especially S8381C, caused weaker staining of lamin A/C at the NE (Fig. 2C and E and Supplementary Material, Fig. S1A), while all three mutants caused weaker staining of SUN2 at the NE, when compared with WT nesprin-1α2 (Fig. 2D and E and Supplementary Material, Fig. S1B). In addition, emerin was mis-localised by both the WT and mutants when compared with GFP alone (Fig. 2E). When the same constructs were transfected into neonatal rat cardiomyocytes (NRCs), IF staining showed that both lamin A/C and SUN2 staining was weaker at the NE with all three mutants compared with WT nesprin-1α2 (Fig. 2F and G and Supplementary Material, Fig S1C and D), indicating nesprin-1 mutants differentially affect the localisation of NE binding partners.

Figure 1. Identification of nesprin-1 variants in DCM patients. Mutation screening in SYNE1 and 2 genes was performed in 218 DCM patients and 210 healthy controls, and identified seven patients harbouring three novel nesprin-1 mutations (R8272Q, S8381C, N8406K, shown in bold) in the C-terminus of nesprin-1 giant (A), equivalent to nesprin-1α, within an evolutionarily conserved region containing the lamin and emerin binding domains (A, B). Previously identified nesprin-1 mutants in DCM (R8212H) and EDMD-CD patients (R8095H, V8387L and E8461K) were also shown (13,14). The KLC binding motif (LEWD) is shown in (B) (24,27).
Figure 2. Overexpression of nesprin-1 mutants caused abnormal nuclear morphology and reduced NE staining of lamin A/C and SUN2. GFP-tagged nesprin-1α2 WT and mutants are shown schematically (A). The full length of this isoform is 977 amino acids, equivalent to amino acids 7875–8796 in nesprin-1 Giant. U2OS cells were transfected with either GFP-nesprin-1α2 WT or mutants. IF staining showed overexpression of mutants, especially S8381C, led to abnormalities in nuclear morphology (B), reduced lamin A/C and SUN2 staining at the NE (C, D, arrowed). The mis-shapen nuclei were measured by circularity, and mislocalisation of lamin A/C, SUN2 and emerin in the transfected cells was quantified by comparing the NE staining in non-transfected cells on the same slide. Graphical representation of the frequency of misshaped nuclei and defects in lamin A/C, SUN2, and emerin at the NE caused by all three mutants (E). At least 100 transfected nuclei were counted in more than three individual experiments and the results are presented as mean ± SEM and also analysed by Student’s t-tests and one-way ANOVA. (*P < 0.05 compared with WT; #: P < 0.05 compared with GFP only). In addition, IF showed both lamin A/C and SUN2 staining at the NE was reduced in the transfected NRCs using GFP-tagged nesprin1α2 mutant S8381C compared with GFP-tagged WT nesprin-1α2 (F, G, arrowed).
Nesprin-1 mutants disrupt the interactions between nesprin-1, lamin A/C and SUN2 within the NE complex

To investigate whether the mutants affected the binding between nesprin-1 and its NE binding partners, GST-tagged WT and mutant nesprin-1α2 constructs lacking the KASH domain (equivalent to nesprin-1 giant amino acids 7875–8662) were generated (Fig. 3A left panel). Protein lysates from un-transfected U2OS cells and transfected cells with Myc-SUN2 (full length) were subjected to GST pull-down using either WT or mutant GST-nesprin-1α2. All three mutants had significantly reduced binding to lamin A/C and SUN2, but not emerin (Fig. 3A right panel, and B) when compared with WT nesprin-1α2. A reverse GST pull-down was also performed. Protein lysates from U2OS cells transfected with either GFP-nesprin-1α2 WT or each of three mutants were subjected to pull-down using either GST-lamin A (amino acids 356–665, containing nesprin-1/2 binding domain) or GST-emerin (amino acids 1–176, lacking the TM domain). The results confirmed all three mutants had significantly reduced binding to lamin A (Fig. 3C), but not

Figure 3. Nesprin-1 mutants affect the interaction between nesprin-1α2 and lamin A/C or SUN2. GST-tagged WT nesprin-1α2 SR1-6 (equivalent to nesprin-1 giant SR 69–74) and mutants are generated and shown schematically (3A left panel, labelled with *), which constructs consisted of 837 amino acids, lacking KASH domain, equivalent to amino acids 7875–8662 of nespin-1 giant. GST pull-down using either GST-WT or mutant nesprin-1 beads showed all three mutants affected binding between nesprin-1 and lamin A/C or SUN2, but not emerin (A, B), which was confirmed by reverse GST pull down by transfecting either GFP-nesprin-1α2 WT or each mutant and using either GST-lamin A (amino acids 356–665) (C) or GST-emerin (amino acids 1–176) beads (D). The binding for each mutant was quantified by densitometry with respect to the input material and expressed as a ratio of the value obtained for WT protein. Three independent experiments were performed shown as mean ± SEM, *P < 0.05 using one-way ANOVA analysis. Coomassie blue staining gel also showed equal amount of GST-nesprin 1α2, lamin or emerin beads used.
emerin (Fig. 3D). Taken together, these data indicated that these nesprin-1 mutations in the 1α2 region cause disruption of the lamin A/C, SUN2 and nesprin-1 complex at the INM.

Nesprin-1 mutants augment activation of extracellular signal-regulated kinase (ERK) pathway

Previous studies have shown that cells harbouring lamin and emerin mutations have altered activation of ERK1/2 (31,32). To investigate whether nesprin-1 defects lead to aberrant ERK1/2 activation, protein lysates from human dermal fibroblasts (HDFs) derived from EDMD and DCM patients carrying either nesprin-1, lamin A/C or emerin mutations (13), and heart tissue from WT and nesprin-1 KASH KO mice with EDMD-like phenotype and DCM (21) were examined. Western blot (WB) showed significant up-regulation of ERK1/2 activity in patient fibroblasts (Fig. 4A) and nesprin-1 KASH KO mouse hearts (Fig. 4B). To determine whether the novel nesprin-1 mutants could also induce activation of ERK1/2 signalling, GFP-nesprin-1α2 WT and mutants, as well as a dominant-negative nesprin-1 KASH (1KASH), which has previously been shown to displace endogenous nesprin-1 and cause NE defects (6,33), were transiently transfected into C2C12 and H9C2 myoblasts. Immunoblotting with antibodies against phosphorylated ERK1/2 (pERK) and total ERK1/2 (tERK) as well as phosphorylated ELK1 (pELK1), a downstream target of ERK1/2, demonstrated that overexpression of the GFP tagged-nesprin-1 mutants and 1KASH increased the amount of pERK1/2 and pELK1 compared with GFP alone or WT nesprin-1α2 in both C2C12 cells (Fig. 4C) and H9C2 cells (Supplementary Material, Fig. S2).

Figure 4. Nesprin-1 mutants cause aberrant activation of MAPKs. WB showed that aberrant activation of pERK was observed in human dermal fibroblasts from EDMD-DCM patients carrying nesprin-1 mutation (V8387L), lamin A/C (R249Q and R401C) and emerin (g.329del59) mutations (A), as well as nesprin-1 KASH KO mice heart collected at 17 and 81 weeks, respectively (B). WB also showed overexpression of all three nesprin-1 mutants and dominant negative-1KASH led to augmented pERK activity compared with WT nesprin-1 and GFP alone (C). GFP empty vector was used for negative control and a dominant negative-1KASH construct as a positive control. Three independent experiments were performed shown as mean ± SEM, *P < 0.05 using one-way ANOVA analysis.
Nesprin-1 mutants lead to dysregulation of myogenic transcription factors

To further investigate if these three novel mutants cause muscle cell dysfunction, we next used the C2C12 mouse myoblast differentiation model. Previous studies showed that mutations in LMNA and overexpression of 1KASH or SUN proteins in C2C12 cells disrupt myoblast differentiation (23,34,35). Myogenesis is driven by myogenic transcription factors (MTFs) such as MyoD and myogenin (36,37). To determine the expression levels of endogenous nesprin-1a, MyoD and myogenin as well as the skeletal muscle specific protein myosin heavy chain (MHC) during the differentiation process, protein lysates were collected at days 0, 2, 4 and 6 following induction (serum withdrawal). WB and/or qPCR showed that endogenous expression levels of nesprin-1a (including both 1a1 and 1a2), MyoD, myogenin and MHC were increased along with myotube formation (Fig. 5A–C, Supplementary Material, Fig. S3). Nesprin-1a levels peaked at day 6, whereas MyoD and myogenin levels peaked at day 2. MHC was detected from day 2 and increased until day 6. Therefore, day 2 for MyoD and myogenin, and day 6 for MHC were chosen as the optimised investigation time points for early and late differentiation in further experiments.

To investigate whether the novel nesprin-1 mutants could disrupt muscle cell differentiation, we used retroviral transduction to generate C2C12 cells stably expressing V5-tagged nesprin-1a2 WT and mutant constructs as well as dominant negative-1KASH, which were cloned into a MIG (IRES-GFP) retroviral vector. GFP protein was expressed independently as a reporter for retroviral infection. Fluorescence-activated cell sorting (FACS) was performed to purify the infected GFP positive populations and these were used in subsequent muscle cell differentiation experiments (Supplementary Material, Fig. S4A, B).

IF staining showed that exogenously expressed V5-tagged WT nesprin-1a2, mutants and 1KASH were observed at the NE in myoblasts (Fig. 6A, Supplementary Material, Fig. S5A). Efficient differentiation of C2C12 cells transduced with eGFP alone (MIG only) or nesprin-1a2 WT was observed, with many multinucleated myotubes formed within 5–6 days. However, fewer myotubes were formed in the cells transduced with either nesprin-1a mutants or 1KASH (Fig. 6B, Supplementary Material, Fig. S5B). Quantification of the fusion index i.e. the percentage of nuclei incorporated into MHC positive multinucleated cells vs. the total number of nuclei, showed a significant reduction in cells transduced with the mutants, in particular, R8272Q and N8406K as well as 1KASH when compared to WT (Fig. 6C). Further analysis of the MHC positive populations revealed that myotubes expressing nesprin-1 mutants contained fewer nuclei compared to the controls (Fig. 6D), indicating a defect in myoblast fusion. Both qPCR and WB showed that the levels of myogenin and MHC were dramatically reduced in cells transduced with the mutants, particularly R8272Q and 1KASH when compared with nesprin-1a2 WT at day 2 and 6 respectively (Fig. 6E–G). qPCR also demonstrated that MyoD was significantly reduced in the cells transduced with 1KASH at Day 2 (Fig. 6E).

Nesprin-1 mutants cause disruption of nesprin-1 and KLC interaction

Recent data showed that nesprin-2 interacts with KLC-1/2 via a conserved ‘LEWD’ motif at the C-terminus of nesprin-2 (27). This motif is also present in nesprin-1 (Fig. 1B)(25–27), suggesting nesprin-1 may also bind to KLC-1/2 and be involved in connecting the nucleus to the microtubule network and therefore play a role in myonuclear positioning. By treatment of C2C12
cells expressing the plasmid containing V5-tagged nesprin-1α2 WT with digitonin or NP-40, we showed that nesprin-1α2 was also localised at the ONM in addition to its previously identified INM localisation where it co-localises and binds to lamin A/C (Supplementary Material, Fig. S6). Therefore, we set out to investigate whether nesprin-1 could also bind to KLC-1/2. GFP-1α2 WT or nesprin-1α2-LEAA (mutated WD/AA within the LEWD motif) were co-expressed with Flag-tagged KLC-2 WT.

Figure 6. Nesprin-1 mutants cause defects in myoblast differentiation. IF showed that exogenously expressed V5-tagged WT-1α2 or mutants and dominant genative-1KASH were localized at the NE. GFP was expressed as a reporter for retroviral infection (A). Upon differentiation, fewer multinucleated myotubes were observed in cells transduced with mutant R827Q and dominant negative-1KASH compared with C2C12 cells transduced with eGFP alone (MG only) or nesprin-1α2 WT (B). The fusion index was reduced in cells transduced with the mutant R827Q and dominant negative-1KASH compared with 1α2 WT (C), more than 600 nuclei for each clone were counted by microscopy (63× objective) at day 6, three independent experiments were performed for each clone. Further analysis of the MHC positive multinucleated populations revealed that myotubes expressing nesprin-1 mutants contained fewer nuclei compared to the controls (D). qPCR and WB showed that nesprin-1 mutant R827Q and dominant negative-1KASH caused significant reduction of myogenin (E, F) and MHC (E, G) levels at DM day 2 and day 6 respectively, qPCR also showed that dominant negative-1KASH caused significant reduction of MyoD (E) levels at DM day 2. All were normalized to GFP, three independent experiments were performed shown as mean ± SEM, *P < 0.05 using Student’s t-tests or two-way ANOVA analysis.
(a dominant light chain isoform in muscle) or the KLC-2 N287L mutant, previously shown to disrupt nesprin-2/KLC binding (27) in U2OS cells. Immunoprecipitation (IP) and WB showed that nesprin-1α2 could efficiently bind to KLC-2, and this binding was disrupted by either mutation (LEAA) in the conserved nesprin-1 LEWD motif or the KLC-2 N287L mutant (27) (Fig. 7A). We then tested the nesprin-1 mutants using this system and found that the R8272Q mutant had significantly reduced binding to KLC-2 compared with nesprin-1α2 WT, while the S8381C mutant appeared to enhance KLC-2 binding (Fig. 7A).

Next we tested whether these mutants affect nesprin-1/KLC-1/2 binding during muscle cell differentiation. Firstly, WB showed that, similar to nesprin-1α, the endogenous expression level of KLC-1/2 increased during myoblast differentiation (Figs. 5B and 7B). Using GST-nesprin-1α2 WT (lacking KASH domain), nesprin-1α2-LEAA and the three mutants, pull-down further confirmed that nesprin-1α2 WT efficiently binds to KLC-1/2, and this binding was disrupted by the mutated LEWD motif-LEAA. In addition, the R8272Q mutant had significantly reduced binding to KLC-1/2 compared with WT in C2C12 cells. This reduced interaction was especially evident in myotubes where expression of these two proteins is highest (Fig. 7C and D). Finally, we tested whether depletion of KLC-1/2 using multiple siRNA oligos would affect fusion of myoblasts and differentiation in a similar manner to that observed in the R8272Q mutant. WB showed the expression levels of both KLC-1 and -2 were reduced in both myoblasts and myotubes after KLC-1/2 depletion (Fig. 8A and B, Supplementary Material, Fig. 5C and D), and IF also showed a reduced KLC-1/2 staining at the NE, however, nesprin-1 remained at the NE (Supplementary Material, Fig. 7A). Moreover, MHC levels and the fusion index were significantly reduced in myotubes upon KLC-2 knockdown (Fig. 8C and D, Supplementary Material, Fig. 7E and F). Further analysis of MHC positive multinucleated cells (myotubes) revealed that KLC-2 depletion resulted in fewer nuclei per myotube (Fig. 8E, Supplementary Material, Fig. 7G) indicating a defect in myoblast fusion. In contrast, KLC-1 depletion led to significantly more clustered nuclei per myotube when compared with controls (Fig. 8E, Supplementary Material, Fig. 7B), indicating a defect in nuclear positioning in addition to myoblast fusion.

Human nesprin-1α2 WT causes heart developmental and conduction defects in zebrafish embryos while mutants induce a less severe heart phenotype

To investigate whether the nesprin mutants affect cardiac structure or function in vivo, we generated a zebrafish model by expressing nesprin-1α2 WT and mutants (R8272Q, S8381C and N8406K) in zebrafish embryos via injection of the corresponding human SYNE1α2 (nesprin-1α2) mRNAs at the one-cell stage. At 48 h post-fertilization (hpf), zebrafish embryos expressing
human nesprin-1α2 WT showed heart defects including dilated atrial chambers with reduced heart rate (Fig. 9A and B, Supplementary Material, video). There was also evidence of abnormal anterior-posterior axis development and curved tails (Supplementary Material, video). Furthermore, whole-mount in situ hybridization (WISH) demonstrated that the expression of myosin light chain polypeptide 7 (myl7), the ortholog of the human regulatory myosin light chain (RLC) gene (38,39), was reduced in 30% of the embryos expressing human nesprin-1α2 WT. The expression pattern of this gene also highlighted the dilated atrial chambers and heart developmental defects such as abnormal looping (Fig. 9C and D; Supplementary Material,
Fig. S8A and B). In contrast, expression of the human nesprin-1<sub>a2</sub> mutants induced some heart developmental defects, such as abnormal heart looping and malpositioning of heart chambers (Supplementary Material, Fig. S8A and B), but without heart enlargement or heart rate defects. There was also evidence of abnormal anterior-posterior axis development in all the embryos, when compared with uninjected and GFP expressed embryos (Supplementary Material, Fig. S8C and D). Taken together these zebrafish larvae data suggests that overexpression of human nesprin-1<sub>a2</sub> WT leads to cardiac developmental defects while nesprin-1<sub>a2</sub> mutants induced a less severe heart phenotype.

Discussion

Mutations in lamin A/C and emerin, which form a complex at the INM, can cause EDMD with conduction system defects, as well as DCM. Similarly, missense mutations in the C-terminal region of the nesprin-1 (SYNE1) and -2 (SYNE2) genes and SUN1/2 genes were identified in EDMD-DCM patients, leading to
disrupted nesprin/lamin/emerin/SUN1/2 interactions and nuclear morphology defects (40,41). In the current study, three novel missense mutations (R8272Q, S8381C and N8406K) were identified in the same C-terminal region of nesprin-1 in DCM patients, which affected nuclear morphology and impaired protein–protein interaction with lamin A/C and SUN2. The mutants also augmented ERK activation in vitro. Importantly, these mutations, especially mutant R8272Q, caused defects in myoblast differentiation associated with dysregulation of MTFs and disruption of the nesprin-1/KLC-1/2 interaction at the ONM. These findings provide new information on how nesprin-1 performs multi-functional roles in muscle cell development and disease via its connections at both INM and ONM, and also how these mutations and disruption of the LINC complex contribute to muscle dysfunction, and potentially the pathogenesis of DCM.

Nesprin-1 mutations interfere with NE organisation

Mutations in the LMNA gene, encoding A-type lamins, cause a number of different tissue specific laminopathies, including DCM (42). The molecular pathogenesis of these diseases is unknown but in some cases may be related to disruption of the LINC complex. Mice lacking A-type lamins display phenotypes that are reminiscent of human muscular dystrophies and cardiomyopathies (43,44). Embryonic fibroblasts derived from LMNA KO mice are characterised with grossly misshapen cell nuclei and a structurally weakened NE, and mislocalization of nesprins leading to reduced mechanical stiffness (45). Mutations in both nesprins and SUN1/2 have also been implicated in EDMD-DCM, whereby mutants cause abnormal localisation of the LINC complex proteins including lamin, emerin and SUN, and disrupted nesprin/lamin/emerin/SUN interactions, leading to defects in nuclear morphology and nuclear-cytoskeletal coupling (13–16). Furthermore, the disruption of endogenous LINC complexes by recombinant dominant negative-KASH constructs of nesprin-1, -2 and -3 also causes a significant loss of mechanical stiffness (6,33,46). Interestingly, the three novel missense mutations (R8272Q, S8381C and N8406K) identified in DCM patients in this study reside within the unique AD region at the C-terminus of the nesprin-1a2 and -1 giant isoforms. The three nesprin-1 mutations (R8272Q, S8381C and N8406K) identified in DCM patients in this study reside within the unique AD region at the C-terminus of the nesprin-1a2 and -1 giant isoforms. The three nesprin-1 mutations (R8272Q, S8381C and N8406K) identified in DCM patients in this study reside within the unique AD region at the C-terminus of the nesprin-1a2 and -1 giant isoforms. The three nesprin-1 mutations (R8272Q, S8381C and N8406K) identified in DCM patients in this study reside within the unique AD region at the C-terminus of the nesprin-1a2 and -1 giant isoforms. The three nesprin-1 mutations (R8272Q, S8381C and N8406K) identified in DCM patients in this study reside within the unique AD region at the C-terminus of the nesprin-1a2 and -1 giant isoforms. The three nesprin-1 mutations (R8272Q, S8381C and N8406K) identified in DCM patients in this study reside within the unique AD region at the C-terminus of the nesprin-1a2 and -1 giant isoforms.
disruption of the functions of all the endogenous nesprin-1 isoforms containing the KASH domain in the transfected cells (19). Interestingly, the R8272Q mutant was able to bind lamin A at comparable levels to the WT nesprin-1, in contrast to weak binding to lamin C. Our current understanding of the interactions between nesprins and lamin A and lamin C remains incomplete, so this apparent binding difference requires further investigation. We did not observe a defect in binding between nesprin-1 mutants and emerin, which is consistent with the notion that mutations in emerin are primarily associated with EDMD rather than DCM (28,47). The data above support possible involvement of LINC complex disruption in the pathogenesis of DCM. Future studies on structure/flexibility of the SRs that are predominantly present in the muscle-specific nesprin isoforms will be required to confirm this hypothesis.

Several studies on LMNA KO and H222P knock-in mice have indicated activation of MAPKs in the development of DCM. Inhibitors of MAPKs could partially rescue the DCM phenotype, implicating ERK in the pathogenesis of lamin A/C cardiomyopathy (48,49). Our data showed that enhanced ERK activity is also observed in heart tissue from the nesprin-1 KASH KO mice, fibroblasts derived from EDMD-DCM patients and nesprin-1 mutant transfected cells, suggesting that nesprin and lamin A/C function through a similar pathway and trigger up-regulation of ERK. Future work will examine how NE proteins regulate ERK activity potentially via influencing interactions between A-type lamin, NE proteins and components of MAPK cascades, as well as nuclear translocation of activated MAPKs (50,51).

**Nesprin-1 mutations and dysregulation of MTFs in myoblast differentiation**

Nesprin-1 mutants are highly expressed in both skeletal and cardiac muscles as previously shown (7,52,53). Although there were no obvious muscle phenotypes recorded, it is plausible that in the patients presenting with the SYNE1 mutations the skeletal muscle dysfunction was too subtle or underestimated at clinical examination. Alternatively, in addition to these SYNE1 mutations, another cardiac disease gene is mutated thus enhancing the phenotype. Therefore, due to restricted accessibility to patient samples, we focused on investigating if these three novel mutants cause muscle dysfunctions by using the C2C12 mouse myoblast differentiation model.

Myogenesis involves a series of sequential steps. Myoblasts originating from the mesoderm are converted to skeletal muscle lineage myoblasts after MyoD expression, enter the cell cycle and proliferate, then withdraw from the cell cycle and initiate differentiation with expression of MTFs such as myogenin (54). Next cell fusion occurs to form multinucleated myotubes and expression of the muscle specific protein MHC. Increasing evidence indicates that multiple cell signalling pathways play critical roles in myoblast fusion, including those involved in cytoskeleton organization, cell adhesion and migration (55) as well as extracellular signalling molecules and components of extracellular matrix (54,56). Recent literature shows that LINC complex components, including nesprins and SUN1/2, mechanically couple the nucleus to the extracellular matrix and play an important role in differentiating muscle. In addition, these proteins have been implicated in regulating chromatin structure and gene expression. For example, C2C12 cells expressing a LMNA R453W mutant have reduced capacity to differentiate, yet retain an unaltered morphology (57), suggesting that subtle abnormal changes in lamina structure or composition may impair the anchoring of chromatin to the NE, affecting gene regulation and perturbing myogenesis.

Using retroviral transduction in mouse C2C12 myoblasts in the current study, our data showed myoblasts expressing mutant nesprin-1WT, R8272Q or dominant negative-1KASH had a significantly lower capacity to differentiate and form multinucleated cells than those expressing 1WT, although exogenously expressed 1WT WT and mutants were observed to be properly localised at the NE. Importantly, the inhibition of multinucleation by dominant negative-1KASH and 1WT mutants, especially R8272Q, is potentially linked to the inhibition of myogenin and MHC expression in the transduced C2C12 cells. Our data also showed that nesprin-1WT was expressed in the initial stage crucial for converting C2C12 myoblasts into myotubes and promoted myoblast differentiation during the process of myotube formation, whereas the mutants reduced or abolished the effects, suggesting that expression of nesprin-1WT mutants does not alter the proliferation of myoblasts, but rather impairs their capacity to express muscle-specific genes (myogenin and MHC). This result in an inability to fuse, especially observed in the R8272Q mutant, which also explains why nesprin-1 mutants affect the expression levels of myogenin more severely than MyoD, because MyoD is already expressed prior to initiation of differentiation at a stage when the expression level of nesprin-1 is still low. Therefore, we propose the following mechanisms whereby nesprin mutants may affect muscle differentiation: regulation of myogenin and expression of MHC are influenced by the LINC complex; nesprin mutants may fail to build a functional scaffold and/or to maintain chromatin compartmentalisation with lamin A/C, leading to an alteration in the amount of heterochromatin formed and/or its localisation. Potentially this causes defects in initiation of the terminal differentiation process resulting in decreased or delayed expression of myogenin and MHC, thus causing a delayed differentiation. This effect may be similar to that observed in C2C12 cells expressing an LMNA R453W mutant (57) that showed a reduced capacity to differentiate. However, further experimentation on how the nesprin-1 mutants affect regulation of MTFs is required to elucidate the precise function of nesprin in muscle cell differentiation.

**Nesprin-1 mutations disrupt nesprin-1/KLC interaction and myoblast fusion**

Proper nuclear positioning and movement is critical in muscle cell differentiation and development. In the nucleus, changes in gene activity that occur during terminal cell differentiation are correlated with gene migration and relocation (58,59). Nuclear movement and positioning are driven by cytoskeletal networks of MTs, actin and/or intermediate filaments and involve a connection between the cytoskeleton and the NE, mediated by the LINC complex (60,61). KO mouse studies have shown that nesprin-1 and SUN1/SUN2 play critical roles in anchoring nuclei in skeletal muscle (62,63). Similarly, mutations identified in SUN1 and SUN2 genes associated with EDMD like phenotypes cause defective nuclear positioning when expressed in mouse fibroblasts (15,16). The MT-based kinesin motor, kinesin-1, consisting of two KHCs and two KLCs, is localised at the NE. Binding of the dominant light chain isoform in muscle, KLC-2, to nesprin-2 has been shown to be responsible for nuclear rotations and movement along MTs (27). There is evidence that nuclear position can influence gene expression. For example, nuclei at the neuromuscular junction (NMJ) have a unique
transcriptional profile relative to the non-synaptic nuclei (59).
Nesprin-1 (SYNE1) levels are much higher in synaptic nuclei
than extrasynaptic nuclei, and also higher in myotubes than
myoblasts in culture and central nuclei during regeneration
(52,64). In addition, maintaining proper nuclear positioning is
thought to ensure sufficient transcriptional capacity and mini-
mise transport distances between the nuclei and the cytoplas-
mal in highly organised long muscle cells (60,65). Our data con-
ﬁrmed that nesprin-1 binds to KLC-1/2, and nesprin-1 mutants,
particularly R8272Q, disrupted this interaction. Furthermore,
depletion of KLC-1 resulted in nuclear clustering, whereas de-
pletion of KLC-2, a dominant muscle isoform, caused reduction
of MHC levels and the fusion index in myotubes, that was con-
sistent with those observed in the R8272Q mutant. This disrup-
tion of nesprin-1/KLC interaction in C2C12 myoblasts may
result in defects in nuclear movement along MTs, leading to ab-
normal nuclear positioning. Further investigations are required
to elucidate the precise roles of nesprin-1 and KLC-1 and -2 in
myonuclear positioning in muscle cell differentiation.

Expression of nesprin-1α2 mutants induce less severe
heart defects during zebrafish heart development
compared to 1α2 WT

To investigate whether the nesprin mutants affect cardiac
structure or function in vivo, we generated a zebrafish model by
expressing human nesprin-1α2 WT and mutants (R8272Q,
S8381C and N8406K) in zebrafish embryos via injection of the
corresponding human SYNE1α2 (nesprin-1α2) mRNAs. Our data
showed that human nesprin-1α2 WT causes heart developmen-
tal and conduction defects in zebrafish embryos, and all three
1α2 mutants caused less severe heart developmental defects.
Although these results are unexpected, there are some potential
explanations. Human nesprin-1α2 is not expressed in the heart
and muscle until the initial stages of muscle cell differentia-
tion (7,52,53). Therefore, injection of human nesprin-1α2 mRNA into
zebraﬁsh larvae at the one cell stage, when the expression level
of endogenous nesprin-1 was minimal, caused ectopic expres-
sion effects on heart development. The effect of the mutants
was less severe potentially because their binding interactions
are compromised leading to less disruption. Future studies uti-
lising the zebrafish model with either cardiac (tissue speciﬁc)/
heat shock protein (timing dependent) promoters or CRISPR/
Cas9-mediated knock-in is required to clarify underlying dis-
ease mechanism.

In summary, our data support the hypothesis that nesprin-1
plays multi-functional roles at both INM and ONM during
muscle cell development and disease (Fig. 10). Although the role
of nesprin-1 dysfunction in DCM requires further experimenta-
tion, we show that novel nesprin-1 mutants affect diverse func-
tions, including gene expression and myoblast fusion and
differentiation. Further investigation is now required to eluci-
date the complex mechanisms behind this dysregulation espe-
cially in the cardiac system.

Materials and Methods
Research subjects

The study cohort consisted of 218 unrelated individuals with
DCM and 210 healthy controls, collected from the West China
Hospital, Sichuan University, China. All blood materials of the
patients and controls included in this study were taken with in-
formed consent for DNA analysis and approval of the local eth-
ics board. The clinical characteristic of the patients and controls
were summarized in Supplementary Material, Table S1 and
Supplementary material. Most of DCM patients were men and
had signiﬁcantly larger left ventricular (LV) chamber and lower
left ventricular ejection fraction (LVEF) when compared with
the ethnic and age-control samples.

Figure 10. Working model for the role nesprin-1. The schematic ﬁgure shows nesprin-1 plays multiple-functions at both INM and ONM, and how mutants can disrupt
the NE-LINC complex, contributing to the pathogenesis of muscle disease. *Indicates where the mutants are.

Human Molecular Genetics, 2017, Vol. 26, No. 12 | 2271
Mutation analysis

Primer pairs were designed across the intron/exon boundaries and untranslated regions of nesprin-1\(_x\) and 1\(_x\), nesprin-2\(_x\), 2\(_x\), 2\(_{2}\), 2\(_{2}\), 2\(_{2}\), and 2\(_{2}\), i.e. the smaller INM localised isoforms of nesprin-1 and nesprin-2 shown to bind emerin and lamin and be either highly or specifically expressed in muscle tissue. 180 oligonucleotide primers from intronic sequences for 88 exons were designed using the program Primer3Input (primer3_www. cgi v 0.2) and used previously (13). Mutation screening was performed using the PCR-based mutation detection technique DHPLC (WAVE 4500B system, Transgenomic). Appropriate DHPLC conditions for running temperatures and buffer gradients were established for each individual exon.

Plasmid constructs/retroviral constructs/site-directed mutagenesis

Human cDNA of nesprin-1\(_x\) WT constructs (amino acids 1–977, equivalent to nesprin-1 giant 7875–8796) were amplified using a high-fidelity GC-rich PCR kit (Roche) and inserted respectively in-frame into the EcoRI site of the pEGFP-C1 vector (Clontech) for overexpression of GFP-nesprin, and the NotI and EcoRI sites of pcDNA3.1(-) vector (Invitrogen) for in vitro synthesis of Flag-tagged nesprin mRNA and microinjection. GST nesprin-1\(_x\), SR1-6 construct (amino acids 1–837, lacking KASH domain, equivalent to nesprin-1 giant 7875–8662, SR 69–74) and V5-tagged nesprin-1\(_x\) construct (amino acids 1–977, equivalent to nesprin-1 giant 7875–8796) were amplified from the established pEGFP-C1-nesprin-1\(_x\)-WT construct and inserted into EcoRI and SalI sites of the pGEX-4T-1 vector (Pharmacia) and EcoRI and NotI sites of the MiClus retrovector respectively. The MiClus vector was a kind gift from Prof. Peter Zammit (66), which was modified from the retroviral (RV) backbone pMSCV-puro (Clontech, Mountain View, CA), in which the puromycin selection gene was replaced with eGFP to create pMSCV–IRES–eGFP, served as the RV control vector and eGFP selection gene was replaced with eGFP to create pMSCV–IRES–puro (Clontech, Mountain View, CA), in which the puromycin selection gene was replaced with eGFP to create pMSCV–IRES–eGFP, served as the RV control vector and eGFP as a reporter for retroviral infection. Retroviruses were then packaged into 293T cells using standard methods as described previously (66). All the constructs of nesprin-1 mutant constructs (R8272Q, S38381C, N4806K) were generated using QuickChange™ XL site-directed mutagenesis kit (Stratagen). Primers for the constructs above are listed in Supplementary Material, Tables S3–S5. Myc-SUN2 has been reported previously (67). CB6-HA-KCL2 WT and mutant n287L were kind gifts from Dr Mark Dodding (King’s College London, UK). GST-lamin A (amino acids 356–665) and GST-emerin (amino acids 1–176) were kind gifts from Dr Juliet Ellis (King’s College London, UK).

Cell nuclei circularity quantification

‘Analyse particles’ function in ImageJ was used to measure circularity of cell nuclei, with circularity values given between 0 and 1 (values closer to 1 being more circular in shape) (68).

Antibodies and immunofluorescence

Primary antibodies were sourced as follows: lamin A/C (N-18, sc-6215, Santa Cruz), SUN2 [kind gifts from Dr Didier Hodzic, University of Washington, US and (67)], emerin (NCL-EMERIN, Novoceastra), GFP (ab290, ab13970, Abcam), GAPDH (sc-25778, Santa Cruz), β-actin (A5316, Sigma), α-tubulin (ab52866, Abcam), phospho-p44/42 MAPK (pERK1/2) (4370, Cell Signalling Technology), p44/42 MAPK (tERK1/2) (9102, Cell Signalling Technology), V5 (R96025, Invitrogen), nesprin-1 (MANNES1A and MANNES1E (52), generated against the C-terminus of the nesprin-1 giant), myogenin (sc-576, Santa Cruz), myosin (clone A4.1025, against all isoforms expressed by MYH1, Alexis Corporation), HA (ab1424, Abcam), KLC-1/2 (63–90, a kind gift from Prof Scott Brady, University of Illinois at Chicago, USA). Alexa fluorophore (488/546/647)-conjugated secondary antibodies were from Invitrogen. HRP-conjugated secondary antibodies were from Amersham. IF staining was performed as described previously (13). In particular, to further define the subcellular localisation for GFP-tagged nesprin-1\(_x\), the transfected cells were fixed by 4% paraformaldehyde/PBS, then permeabilized using either 0.01% digitonin/PBS or 0.5% NP40/PBS.

Cell culture, transfection and RNAi

HDFs, U2OS, C2C12 myoblasts were cultured at 37 °C/5% CO\(_2\) in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1% Pen-Strep-Glutamine (PSG). For myoblast differentiation, C2C12 were cultured in low-mitogen medium (DMEM supplemented with 1% PSG and 2% horse serum) as described previously (7). For transient transfection, cells were plated onto glass coverslips or T25 flask at approximately 1.2 × 10^5 cells/ml and transfected using FuGENE HD™ (Promega) according to the manufacturer’s instructions and fixed for IF staining or harvested for Western blotting 24 h after transfection as described previously (7,13). siRNA transfections were also performed by using HiPerFect (Qiagen) according to the manufacturer’s instructions. KLC-1/2 siRNA oligomers targeting to the mouse KLC-1/2 were previously described (27) and obtained from Dharmacon, named as KLC-1A and KLC-2A. Additional four KLC-1/2 siRNA oligos obtained from Qiagen (Cat. No: SI01085154, SI01085168, SI01083327 and SI01083341) were renamed as KLC-1B and -1C, KLC-2B and -2C respectively. Allstars negative control siRNA was also supplied from Qiagen.

Neonatal rat cardiomyocytes (NRCs) isolation, culture and transfection

Primary cultures of NRCs were isolated from 1- or 2-day-old neonatal Sprague–Dawley rats. Hearts were collected and atria were removed. Hearts were then washed, excised, minced and enzymatically digested at 37 °C with ADS buffer [116 mmol/L NaCl, 20 mmol/L HEPES, 0.8 mmol/L NaH_{2}PO_{4}, 5.6 mmol/L glucose, 5.4 mmol/L KCl, 0.8 mmol/L MgSO_{4} containing collagenase (57.5 U/ml) and pancreatin (1.5 mg/mL)]. The suspension was pre-plated to remove contaminating cells, before being cultured on gelatin (Sigma) pre-coated 35 mm petri dishes with a density of 2 × 10^5 cells/ml. Cells were allowed to adhere for 24 h, and then transfected using Escort III (Sigma) following the manufacturer’s instructions as described previously (69).

Retroviral infection and myoblast differentiation

Retroviral constructs, together with an ectopic packaging plasmid, were transiently co-transfected into 293T cells to produce non-replicating retrovirus and the supernatant harvested 48, 60 and 72 h later. Retroviral infection was performed as described previously (66). Briefly, C2C12 cells were plated in T25 flasks. After 24 h, the medium was replaced with a 1:5 dilutions of 293T retroviral supernatant supplemented with 4 μg/ml polybrene and incubated at 37 °C for 4-6 h, and then changed into fresh medium. FACS was performed to purify the infected GFP
positive cells in 48 h and these were used to in subsequent myoblast differentiation experiments. To induce differentiation, the medium was replaced with the differentiation medium (DM) containing 2% horse serum and 1% PSG, and cell lysates were collected for further investigation at day 0, 2, 4 and 6.

**Co-immunoprecipitation assays**

U2OS cells were transfected using GFP-nesprin-1\_2 WT/mutants with HA-KLC-1/2 WT/mutant as well as Myc-SUN2 respectively, harvested about 24 h later and kept in IP buffer [10 mM Tris (pH 7.4), 50 mM NaCl, 5 mM EDTA, 1% Triton X-100] with protease inhibitor cocktail (Sigma) on ice for 30 min, followed by 10 s sonication and centrifugation. About 500 µg of protein was pre-cleaned with Protein A/G sepharose beads (Sigma) for 1 h at 4°C. Beads were removed by centrifugation and 2.5 µg primary antibody was added to lysates and left rotating at 4°C for 16 h. Beads were then added to reactions and incubated for 2 h rotating at 4°C. Samples were centrifuged and supernatant discarded. Pellets were washed and re-suspended in sample buffer, heated at 95°C for 10 min and analysed by WB as described previously (13).

**GST pull-down assays**

GST fusion proteins and GST alone were induced from 100 ml of bacterial culture for 4 h by addition of 0.2 mM isopropyl-1-thio-β-D-galactopyranoside. Purification of the proteins was performed according to the Amersham Biosciences protocol using glutathione-Sepharose 4B beads (Amersham Biosciences). Pull-down assays were performed as described previously (70). Briefly, 200 µg extracts from U2OS or C2C12 myoblasts/myotubes were incubated with 50 µl beads with constant rotation for 16 h at 4°C. Bound proteins were washed and eluted into sample buffer, followed by WB. In particular, to investigate the interaction between nesprin-1 and its NE binding partners, protein lysates from Myc-SUN2 transfected (for SUN binding) and untransfected U2OS cells (for lamin A/C and emerin binding), C2C12 myoblast and myotubes (for KLC-1/2 interaction) were harvested and subjected to pull down using either GST-WT or mutant nesprin-1\_2 SR1-6 beads. To further confirm the bindings, U2OS cells were transfected with either GFP-nesprin-1\_2 WT or mutants, protein lysates were harvested and subjected to pull-down using either GST-lamin A (amino acids 356–665) or GST-emerin (amino acids 1–176).

**Quantitative RT-PCR (QPCR)**

C2C12 Cells were cultured in T25 flasks in proliferation or differentiation medium. Total RNA was extracted using RNA-STAT 60 (Amsbio) according to manufacturer’s protocol. Reverse transcription synthesis of cDNA and qPCR was performed as described previously (13). Relative expression of each myogenic transcriptional factor between proliferating and differentiated cells was measured in three replicates in at least three independent experiments. Primers for myogenin, MHC, MyoD, V5 and GFP have been previously described and listed in Supplementary Material, Table S6.

**Zebrafish embryos**

WT embryos from AB strain were used. Embryos were obtained by natural matings and cultured in embryo medium (71). Staging of the embryos was carried out as described by Kimmel et al. (72). Ethical approval was obtained from the Animal Care and Use Committee of Sichuan University.

**In vitro synthesis of mRNA and microinjection**

Capped GFP and nesprin mRNAs were synthesized using mMESSAGE mMACHINE® Kit (Ambion); Synthetic capped mRNAs were injected into single-cell embryos. Injection dose (60 mg) was an optimised amount received by a single embryo.

**Zebrafish whole-mount in situ hybridization**

Whole-mount in situ hybridization was carried out as previously described (73,74). After linearization by appropriate restriction enzymes, antisense RNAs for in situ hybridization were synthesized using DIG RNA Labelling Kit (SP6/T7) (Roche) and purified by MEGAEclear (Ambion). Signal area of whole-mount in situ hybridization was measured by software ImageJ.

**Statistical analysis**

Cell counts for statistical analysis were performed on n = 100–200 cells/n = 10 confocal microscope fields (63× magnification) for each control and experimental group, and results were verified in at least three independent experiments. The data were analysed using GraphPad Prism software by the Student’s t-tests, One way or Two-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test for two independent groups or multiple comparisons, respectively. The values are expressed as mean ± standard error of mean (SEM). The P-values < 0.05 were considered statistically significant.

**Supplementary Material**

Supplementary Material is available at HMG online.

**Acknowledgements**

We thank the patients for their participation to the study, Dr Yaniv Hinits (King’s College London) for his advice and critical comments on Zebrafish experiments, Dr Andrew Cobb (King’s College London) for critical reading of this manuscript, Dr Flavia Autore and Miss Aisling Williams (King’s College London) for their help with the artwork.

**Conflict of Interest statement.** None declared.

**Funding**

British Heart Foundation (BHF), UK [PG/11/58/29004 to Q.P.Z., RG/11/14/29056 to C.M.S., PG/11/71/29091 to I.H. and G.E.M.]; National Natural Science Foundation of China [81270289 to L.R.]. Funding to pay Open Access publication charges for this article was provided by the BHF.

**References**


